ADARx Pharmaceuticals, Inc.

Quick facts

Phase 3 pipeline

• ADX-324 · Genetic/Rare Disease
  ADX-324 is an ADAR enzyme activator that enhances adenosine-to-inosine RNA editing to modulate gene expression and protein function.
• ADX-324 Dose Level 1 · Immunology / Autoimmune
  ADX-324 is an ADAR inhibitor that reduces adenosine-to-inosine RNA editing to modulate immune and inflammatory responses.
• ADX-324 Dose Level 2 · Oncology
  ADX-324 is an ADAR1 inhibitor that modulates RNA editing to enhance innate immune responses against cancer.

Phase 2 pipeline

• ADX-038 · Immunology
  ADX-038 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.
• ADX-038 Dose Level 1 · Oncology
  ADX-038 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.
• ADX-038 Dose Level 2

Phase 1 pipeline

• ADX-626
• ADX-850

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• ADARx Pharmaceuticals, Inc. portfolio CI brief
• ADARx Pharmaceuticals, Inc. pipeline updates RSS